Seagen
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Seagen sits in the top decile of US sponsors by registered trial count (#270 of 15,742 sponsors by registered trial count).
Seagen: 84 sponsored US clinical trials, none currently recruiting.
Seagen sponsors 84 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 56 completed. 3 of these trials are in Phase 3-4 (later-stage) and 81 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Large B-Cell, Diffuse, with 2 trials.
Top-decile sponsor footprint
Seagen ranks in the top decile of sponsors by registered trial count (#270 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
56 of 84 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (66.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
84 total, page 1 of 2
A Study of SGN-ALPV in Advanced Solid Tumors
NCT05229900
A Study of SEA-CD40 Given With Other Drugs in Cancers
NCT04993677
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
NCT04499924
A Study of SGN-STNV in Advanced Solid Tumors
NCT04665921
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
NCT04254107
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
NCT03947255
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT04032704
A Study of SGN-CD228A in Advanced Solid Tumors
NCT04042480
A Safety Study of SGN-CD47M in Patients With Solid Tumors
NCT03957096
A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects
NCT03914755
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
NCT03657043
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
NCT03826602
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
NCT03646123
Effects of Tucatinib on Cardiac Repolarization in Healthy Participants
NCT03777761
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
NCT03582033
A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects
NCT03722823
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
NCT03723395
A Trial of Tisotumab Vedotin in Cervical Cancer
NCT03438396
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
NCT03310957
A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
NCT03379584
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
NCT03245736
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
NCT03043313
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
NCT02952989
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
NCT02954796
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT02855359
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
NCT02848248
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02785900
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
NCT02702141
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
NCT02706899
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
NCT02614794
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
NCT02552121
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
NCT02614560
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
NCT02572167
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
NCT02594163
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
NCT02592876
Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus
NCT02533570
Safety Study of SEA-CD40 in Cancer Patients
NCT02376699
A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
NCT02326584
Safety Study of SGN-CD70A in Cancer Patients
NCT02216890
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
NCT01983501
A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
NCT02025192
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
NCT02001623
A Safety Study of SGN-LIV1A in Breast Cancer Patients
NCT01969643
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
NCT01925612
A Safety Study of SGN-CD33A in AML Patients
NCT01902329
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
NCT01874054
A Safety Study of SGN-CD19A for B-Cell Lymphoma
NCT01786135
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
NCT01786096
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
NCT01777152
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
NCT01716806
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 50 |
| Phase 2 | 31 |
| Phase 3 | 3 |
Therapeutic Areas
How the Seagen early-phase archive is shaped
84 indexed studies, none listed as recruiting (0% open); 56 completed (67%).
Phase mix: 3 late (III/IV) vs 81 early (I/II) (early-phase heavy).
Top condition: Lymphoma, Large B-Cell, Diffuse (2 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Seagen: archived-pipeline peers nationwide
Peers matched on 84 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Seagen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 84 archived trials
- Intermountain Health Care · 85 trials · 13% recruiting
- Ipsen · 85 trials · 19% recruiting
- Ferring Pharmaceuticals · 83 trials · 5% recruiting
- National Jewish Health · 83 trials · 8% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Seagen page
84 registered trials is a research-attention snapshot, not an endorsement of Seagen or any single study.
- None of Seagen's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lymphoma, Large B-Cell, Diffuse is the condition Seagen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Large B-Cell, Diffuse trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Seagen pipeline card: 84 registered trials from official public datasets.Report a data error.